HCWB · HCW Biologics Inc.
$1.17
+0.05 (+4.46%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company believes that substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the date of issuance of the Company's condensed financial statements, without additional funding or financial support. After considering management's plan for financing and funds raised that are probable to occur within one year, as well as that the Company expects to continue to incur losses from operations for the foreseeable future, management concluded that the substantial doubt that existed in its going concern analysis as of June 30, 2026 was not alleviated.”View the 10-Q filed Aug 14, 2026
Market Cap
$2.15M
Shares
1.84M
Volume · Oct 23
80.64K
Avg daily vol (3M)
405.37K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.17
Open$1.12
Day$1.09–1.19
52W close$1.12–23.52
Avg vol 30d606K
Short int61K · 3.3% float · 1.0d
Short vol31%
Last earningsNov 7, 2025
DataJul 2021–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$6.66M
Trailing 12 months
Net income (TTM)
−$5.58M
Trailing 12 months
Revenue growth YoY
+1,758.5%
Year over year
Operating margin
-115.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$5.82M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+347.6%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
3.3%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 19.5 · elevated
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−73%
below
Price vs 50-day avg
−43%
below
RSI (14)
29
oversold
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−39%
trailing
6-month return
−52%
trailing
YTD return
−80%
this year
Relative strength
−58%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-20% holders QoQ · +3 funds added
Insider flow
Accumulating
Net +$100.0K over 90 days · 0% sells
Short interest
Rising
3.32% of float · ▲ +557.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
12 holders — mid 3-yr range
Squeeze score
51
elevated · 0–100
Fundamentals
Gross margin
0%
EPS growth
+66%
Y/Y
Free cash flow
$-13.4M
Balance sheet
$4.9M
net debt
Quant / Vol
risk profile
Volatility
331%
annualized · 1-yr
Max drawdown
−95%
past year
ATR
14.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−73%
Bearish
Price vs 50-day avg
−43%
Bearish
RSI (14)
29
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-20% holders QoQ · +3 funds added
Insider flow
Accumulating
Net +$100.0K over 90 days · 0% sells
Short interest
Rising
3.32% of float · ▲ +557.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
12 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $24
vs 200-day avg -73%
vs 50-day avg -43%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HCWB
this stock
HCW Biologics Inc.
|
$2.15M | — | -97.9% | — | 3.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.80B | +15.6% | +46.2% | 30.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.88B | +4.3% | +20.8% | 19.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.89B | +578.5% | +4.3% | — | 7.7% |
|
CSLLY
Csl Ltd
|
$66.42B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
SEC Filings
Latest
S-1
- Filed
- Oct 2, 2026
- This year
- 45
HCW Biologics Inc. registered the resale of up to 1,807,228 common shares from September 2026 PIPE warrants; pre-funded warrants cover 903,614 shares and common warrants cover 903,614 shares pending stockholder approval.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HCWB | -5.7% | -39.4% | -52.4% | -31.6% | -79.9% |
| SPY | -0.4% | -1.5% | +5.8% | -0.4% | +11.5% |
| vs SPY | -5.2% | -37.9% | -58.3% | -31.2% | -91.4% |